Cigarette smoking strongly modifies the association of complement factor H variant and the risk of lung cancer

Cancer Epidemiology

Volumn 36, Issue 2, 2012, Pages

  Zhang, Zhi ^a,c   Yu, Dianke ^b   Yuan, Juxiang ^c   Guo, Yongli ^b   Wang, Hongge ^c   Zhang, Xuemei ^c  

^a TANGSHAN GONGREN HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c HEBEI UNITED UNIVERSITY   (China)

Author keywords

CFH; Complement factor F; Genetic variants; Lung cancer; Polymorphism

Indexed keywords

COMPLEMENT FACTOR H; HISTIDINE; TRYPTOPHAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CHINESE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENOTYPE; HEALTH BEHAVIOR; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; UNDIFFERENTIATED CARCINOMA;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLEMENT FACTOR H; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING;

EID: 84858796725     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.11.004     Document Type: Article

References (42)

1. Alberg A.J., Samet J.M. Epidemiology of lung cancer. Chest 2003, 123(Suppl. 1):21S-49S.
2. Stavrides J.C. Lung carcinogenesis: pivotal role of metals in tobacco smoke. Free Radic Biol Med 2006, 41(7):1017-1030.
3. Sengupta N., MacFie T.S., MacDonald T.T., Pennington D., Silver A.R. Cancer immunoediting and " spontaneous" tumor regression. Pathol Res Pract 2010, 206(1):1-8.
4. Reiman J.M., Kmieciak M., Manjili M.H., Knutson K.L. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007, 17(4):275-287. PMCID: 2742305.
5. Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006, 90:1-50.
6. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immun 2002, 3(11):991-998.
7. Arum C.J., Anderssen E., Viset T., Kodama Y., Lundgren S., Chen D., et al. Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer. Neoplasia 2010, 12(6):434-442. PMCID: 2887496.
8. Tang C., Ang B.T., Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J 2007, 21(14):3777-3785.
9. Varan A., Buyukpamukcu M., Ersoy F., Sanal O., Akyuz C., Kutluk T., et al. Malignant solid tumors associated with congenital immunodeficiency disorders. Pediatr Hematol Oncol 2004, 21(5):441-451.
10. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996, 61(2):274-278.
11. Fernandez-Gonzalez A.L., Espana A., Redondo P. Solid tumors after heart transplantation. Ann Thorac Surg 1996, 62(3):943-944.
12. Pham S.M., Kormos R.L., Landreneau R.J., Kawai A., Gonzalez-Cancel I., Hardesty R.L., et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995, 60(6):1623-1626.
13. Bichari W., Bartiromo M., Mohey H., Afiani A., Burnot A., Maillard N., et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant Proc 2009, 41(2):672-673.
14. Pfeffer P.F., Hansen S., Leivestad T., Fauchald P., Brekke I.B., Sodal G. Cancer risk after renal transplantation in the Norwegian transplant program. Transplant Proc 1995, 27(1):979-980.
15. Rutkowski M.J., Sughrue M.E., Kane A.J., Mills S.A., Parsa A.T. Cancer and the complement cascade. Mol Cancer Res 2010, 8(11):1453-1465.
16. Pangburn M.K., Pangburn K.L., Koistinen V., Meri S., Sharma A.K. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol 2000, 164(9):4742-4751.
17. Ollert M.W., David K., Bredehorst R., Vogel C.W. Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J Immunol 1995, 155(10):4955-4962.
18. Carreno M.P., Labarre D., Maillet F., Jozefowicz M., Kazatchkine M.D. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Eur J Immunol 1989, 19(11):2145-2150.
19. Pryzdial E.L., Isenman D.E. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact. J Biol Chem 1987, 262(4):1519-1525.
20. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., et al. Modulation of the antitumor immune response by complement. Nat Immun 2008, 9(11):1225-1235. PMCID: 2678913.
21. Ajona D., Castano Z., Garayoa M., Zudaire E., Pajares M.J., Martinez A., et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 2004, 64(17):6310-6318.
22. Giannakis E., Jokiranta T.S., Male D.A., Ranganathan S., Ormsby R.J., Fischetti V.A., et al. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol 2003, 33(4):962-969.
23. Jarva H., Jokiranta T.S., Hellwage J., Zipfel P.F., Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999, 163(7):3957-3962.
24. Sjoberg A.P., Trouw L.A., McGrath F.D., Hack C.E., Blom A.M. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol 2006, 176(12):7612-7620.
25. Mold C., Gewurz H., Du Clos T.W. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999, 42(1-3):23-30.
26. Yu H., Munoz E.M., Edens R.E., Linhardt R.J. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim Biophys Acta 2005, 1726(2):168-176.
27. Li M., Atmaca-Sonmez P., Othman M., Branham K.E., Khanna R., Wade M.S., et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet 2006, 38(9):1049-1054. PMCID: 1941700.
28. Zareparsi S., Branham K.E., Li M., Shah S., Klein R.J., Ott J., et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005, 77(1):149-153. PMCID: 1226187.
29. Kim I.K., Ji F., Morrison M.A., Adams S., Zhang Q., Lane A.M., et al. Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration. Mol Vis 2008, 14:1487-1495. PMCID: 2515825.
30. Magnusson K.P., Duan S., Sigurdsson H., Petursson H., Yang Z., Zhao Y., et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006, 3(1):e5. PMCID: 1288033.
31. Zhang X., Miao X., Liang G., Hao B., Wang Y., Tan W., et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005, 65(3):722-726.
32. Chaturvedi A.K., Caporaso N.E., Katki H.A., Wong H.L., Chatterjee N., Pine S.R., et al. C-reactive protein and risk of lung cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2010, 28(16):2719-2726. PMCID: 2881850.
33. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009, 9(10):729-740.
34. Amornsiripanitch N., Hong S., Campa M.J., Frank M.M., Gottlin E.B., Patz E.F. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 2010, 16(12):3226-3231. PMCID: 2891404.
35. Okemefuna A.I., Nan R., Miller A., Gor J., Perkins S.J. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem 2010, 285(2):1053-1065. PMCID: 2801232.
36. Laine M., Jarva H., Seitsonen S., Haapasalo K., Lehtinen M.J., Lindeman N., et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007, 178(6):3831-3836.
37. Skerka C., Lauer N., Weinberger A.A., Keilhauer C.N., Suhnel J., Smith R., et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol 2007, 44(13):3398-3406.
38. Robbins R.A., Nelson K.J., Gossman G.L., Koyama S., Rennard S.I. Complement activation by cigarette smoke. Am J Physiol 1991, 260(4 Pt 1):L254-L259.
39. Kew R.R., Ghebrehiwet B., Janoff A. Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement. J Clin Invest 1985, 75(3):1000-1007. PMCID: 423647.
40. Esparza-Gordillo J., Soria J.M., Buil A., Almasy L., Blangero J., Fontcuberta J., et al. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 2004, 56(2):77-82.
41. Loeffler D.A., Camp D.M., Schonberger M.B., Singer D.J., LeWitt P.A. Early complement activation increases in the brain in some aged normal subjects. Neurobiol Aging 2004, 25(8):1001-1007.
42. Hecker L.A., Edwards A.O., Ryu E., Tosakulwong N., Baratz K.H., Brown W.L., et al. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 2010, 19(1):209-215. PMCID: 2792151.